KR970705996A - 5알파-환원 효소 저해제(5alpha-reductase inhibitors) - Google Patents
5알파-환원 효소 저해제(5alpha-reductase inhibitors)Info
- Publication number
- KR970705996A KR970705996A KR1019970701783A KR19970701783A KR970705996A KR 970705996 A KR970705996 A KR 970705996A KR 1019970701783 A KR1019970701783 A KR 1019970701783A KR 19970701783 A KR19970701783 A KR 19970701783A KR 970705996 A KR970705996 A KR 970705996A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- group
- formula
- phenyl
- Prior art date
Links
- 239000002677 5-alpha reductase inhibitor Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims 32
- -1 azinaphthalenyl Chemical group 0.000 claims 31
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 5
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 3
- 239000000376 reactant Substances 0.000 claims 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- IHNINSVQYKIZIC-UHFFFAOYSA-N 2h-quinolin-3-one Chemical compound C1=CC=CC2=CC(=O)CN=C21 IHNINSVQYKIZIC-UHFFFAOYSA-N 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001351 alkyl iodides Chemical class 0.000 claims 1
- 125000005870 benzindolyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000006604 di(C1-C3 alkyl) aminosulfonyl group Chemical group 0.000 claims 1
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 claims 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- YEXWPTQVHNJMNW-UHFFFAOYSA-N 2h-benzo[h]quinolin-3-one Chemical class C1=CC=C2C=CC3=CC(=O)CN=C3C2=C1 YEXWPTQVHNJMNW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
일련의 벤조퀴놀린-3-온은 I-형 및 Ⅱ-형 5α -환원 효소에 의해 야기된 상태를 치료하는데 효율적인 약제이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 화학식(I)의 화합물 또는 그의 약학적으로 허용가능한 염:상기식에서, R 및 R1은 둘다 수소를 나타내거나 함께 단일결합을 형성하고; R2는 수소 또는 C1-C3알킬을 나타내고; R3은 메틸 또는 에틸을 나타내고; R4및 -X-R5는 각각 7-, 8-, 및 9- 위치중 하나에 위치하고; R4는 수소, 할로, 메틸, 또는 에틸을 나타내고; X는 C1-C4알킬, C2-C4알케닐, C2-C4알키닐, 단일결합, -SO-, -SO2-, -CO-Y-(CH2)n, -Y-CO-(CH2)n, -CO-, -Z-(CH2)n-, 또는 -SO3-를 나타내고(여기서, 비대칭인 X그룹은 어떠한 배향으로도 존재할 수 있다.); Y는 -S-, -O-, 또는 -NH-를 나타내고; Z는 -O- 또는 -S-를 나타내고; n은 0 내지 3을 나타내고; R5는 페닐, 나프탈레닐, 피리디닐, 피라지닐, 피리다지닐, 피리미디닐, 안트라세닐, 아새나프탈레닐, 티아졸릴, 벤즈이미다졸릴, 인다졸릴, 티오페닐, 페난트레닐, 퀴놀리닐, 플루오레닐, 이소퀴놀리닐, 인다닐, 벤조피라닐, 인돌릴, 벤즈이소퀴놀리닐, 벤즈인돌릴, 벤조티아졸릴, 벤조티오페닐, 퀴녹살리닐, 벤즈옥사졸릴, 테트라졸릴, 나프토티아졸릴, 퀴나졸리닐, 티아졸로피리디닐, 피리다지노퀴나졸리닐, 벤즈이소티아졸릴, 벤조디옥솔릴, 벤조디옥시닐, 디페닐메틸 또는 트리페닐메틸을 나타내고; 상기 R5그룹은 비치환되거나 할로, 트리플루오로메틸, 트리플로오로메톡시, C1-C4알킬, 트리플로오로메톡시, 하이드록시, C1-C3알콕시, 니트로, C1-C3알킬티오, C1-C6알킬노일, 페닐, 옥소, 페녹시, 페닐티오, C1-C3알킬설피닐, C1-C3알킬설포닐, 시아노, 아미노, C1-C3알킬아미노, 디페닐메틸아미노, 트리페닐메틸아미노, 벤질옥시, 벤질티오, (모노-할로, 니트로, 또는 CF3)벤질(옥시 또는 티옥),디(C1-C3알킬,C3-C6사이클로알킬, 또는 C4-C8사이클로알킬알킬)아미노, (모노-C1-C3알킬,C1-C3)알콕시, 또는 할로)-(페닐, 페녹시, 페닐티오, 페닐설포닐, 또는 페녹시포닐), C2-C6알카노일아미노, 벤조일아미노, 디페닐메틸아미노(C1-C3알킬), 아미노카보닐, C1-C3알킬아미노타보닐, 디(C1-C3알킬)-아미노카보닐, 할로-C1-C3알카노일, 아미노설포닐, C1-C3알킬아미노설포닐, 디(C1-C3알킬)아미노설포닐, 페닐(옥시 또는 티오)(C1-C3알킬), (할로, C1-C3알킬 또는 C1-C3알콕시)페닐(옥시 또는 티오)(C1-C3알킬),벤조일, 또는(아미노, C1-C3알킬아미노 또는 디(C1-C3알킬)아미노(C1-C3알킬)로 구성된 그룹으로부터 선택된 1 내지 3개의 그룹으로 치환되거나; 또는 상기 R5그룹은 모폴리노(C1-C3알킬)그룹, 페닐(C1-C3알킬)피페리디닐 그룹, 페닐(C1-C3알킬)피페리디닐아미노카보닐 그룹, C2-C6알카노일아미노티오페닐 그룹, 또는(아미노, C1-C3알킬아미노 또는 디(C1-C3알킬)아미노)나프탈레닐설포닐아미노 그룹으로 치환되거나; 또는 R5는 퍼할로페닐 그룹이다.
- 제1항에 있어서, R 및 R5둘다가 수소를 나다내는 화합물.
- 제2항에 있어서, R3가 메틸을 나타내는 화합물.
- 제3항에 있어서, R2가 메틸 또는 수소를 나타낸 화합물.
- 제1항에 있어서, R4가 수소를 나타낸 화합물.
- 제3항에 있어서, X가 -CO-, -CO-Y-(CH2)n-, -Z-(CH2)n-, 알킬, 또는 단일결합을 나타내는 화합물.
- 제6항에 있어서, X가 단일결합 또는 황 원자를 나타내는 화합물.
- 제7항에 있어서, R5가 페닐, 나프탈레닐, 피리디닐, 피라지닐, 피리다지닐, 피리미디닐, 안트라세닐, 페난트레닐, 플루오레닐, 또는 아세나프탈레닐을 나타내고, 이들 R5그룹이 치환되거나 또는 비치환되는 화합물.
- 제7항에 있어서, R5가 벤조피라닐, 벤조티아졸릴, 벤조티오페닐, 또는 벤즈이소티아졸릴을 나타내고, 이들 R5그룹이 치환되거나 또는 비치환되는 화합물.
- 제1항에 있어서, (+)-(4aR)-(10bR)-4-메틸-8-(4-에틸-2-벤조티아졸릴티오)-10b-메틸-1,2,3,4,4a,5,6,10b-옥타하이드로벤조[f]퀴놀린-3-온인 화합물 또는 그의 약학적으로 허용가능한 염.
- 하나 이상의 약학적으로 허용가능한 담체와 함께, 활성 성분으로서 제1항 내지 제10항 중 어느 한 항에 따른 화학싱(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염을 포함하는 약학 제제.
- 과도한 5α-환원 활성에 의해 야기된 상태를 치료하는데 사용하기 위한, 제1항 내지 제10항 중 어느한 항에 따른 화학식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염.
- 양성 전립선 과증식증을 치료하는데 사용하기 위한. 제 1항 내지 제10항중 어느 한 항에 따른 화학식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염.
- 테트라하이드로푸란, 디메톡시에탄, 디에톡시에탄, 및 메틸 t-부틸 에테르로 구성된 그룹으로부터 선택된 유기 용매, 및 수성 수산화 나트륨 또는 수산화 칼륨을 포함하는 반응 혼합물중에서, 하기 화학식(B)의 화합물을 요오드화 메틸, 요오드화 에틸 또는 요오드화 n-프로필과 반응시키는 것을 포함하는, 하기 화학식(A)화합물의 제조방법:상기식에서, R2′는 메틸, 에틸 또는 n-프로필이고; R3′는 수소 또는 메틸이고; R4는 수소, 할로, 메틸 또는 에틸이고;R5′는 할로, 니트로, 시아노, C1-C6알킬, 트리플루오로메틸 또는 C1-C6알콕시이거나; 또는 R5′는 A가 C1-C6알킬, C2-C6알케닐, 또는 C2-C6알키닐인 -A-R6그룹이거나; 또는 R5′는 X′가 C1-C4알킬, C2-C4알케닐, C2-C4알키닐 또는 단일결합인 -X′-R7그룹이고; R6은 할로, 트리플루오로메틸, 또는 C1-C6알콕시이고; R7은 페닐, 나프탈레닐, 피리디닐, 피라지닐, 피리다지닐 피리미디닐르 안트라세닐, 아세타프탈레닐, 티아졸릴, 벤즈이미다졸릴, 인다졸릴, 티오페닐, 페난트레닐, 퀴놀리닐, 플푸오레닐, 이소퀴놀리닐, 인다닐, 벤조피라닐, 인돌릴, 벤즈이소퀴놀리닐, 벤즈인돌릴, 벤조티아졸릴, 벤조티오페닐, 퀴녹살리닐, 벤즈옥사졸릴, 테트라졸릴, 나프토티아졸릴, 퀴나졸리닐, 티아졸로피리디닐, 피리다지노퀴나졸리닐, 벤즈이소티아졸릴, 벤조디옥솔릴, 벤조디옥시닐, 디페닐메틸 또는 트리페닐메틸이고; 상기 R7그룹은 비치환되거나 또는 할로, 트리플루오로메틸, 트리플루오로에톡시, C1-C4알킬, 트리플루오로메톡시, 하이드록시, C1-C3알콕시, 니트로, C1-C3알킬티오, C1-C6알카노일, 페닐, 옥시, 페녹시, 페닐티오, C1-C3알킬설포닐, 시아노, 벤질옥시, 벤질티오, (모노-할로, 니트로 또는 트리플루올메틸)벤질(옥시 또는 티오),(모노-C1-C3알킬, C1-C3알콕시 또는 할로)-(페닐, 페녹시, 페닐티오, 페닐설포닐 또는 페녹시설포닐), 할로-C1-C6알카노일, 페닐(옥시 또는 티오)(C1-C3알킬), (할로, C1-C3알콕시)페닐(옥시 또는 티오)(C1-C3알킬), 또는 벤조일로 구성된 그룹으로부터 선택된 1 내지 3개의 그룹으로 치환되거나; 또는 상기 R7그룹은 모폴리노(C1-C3알킬)그룹, 또는 페닐(C1-C3알킬)피페리디닐 그룹으로 치환되거나; 또는 R7은 퍼할로페닐 그룹이다.
- (a) 하기 화학식(Ⅱ)의 중간 생서물을 활성화된 형태로 화학식 X-R5의 화합물과 반응시키거나, 활성화된 형태의 화학식(Ⅱ)의 화합물을 화학시 L-X-R5의 화합물가 반응시키고;(b)화학식(Ⅱ)의 화합물을 화학식 -X-R5의 화합물과 반응시키거나. -L이 -Z에 의해 치환된 화학식(Ⅱ)의 화합물을 화학식 L-X-R5의 화합물과 반응시켜 X가 -Z-(CH2)n-인 화학식(Ⅰ)의 화합물을 제조하고; (c) -L이 -YH, -CO-L, -(CH2)n-YH, 또는 -(CH2)n-CO-L 중 하나로 치환된 화학식(Ⅱ)의 화합물을 화학식 HY-R5, L-CO-R5, HY-(CH2)n-R5, 또는 L-CO-(CH2)n-R5중 하나의 화합물과 반응시켜 X가 -CO-Y-(CH2)n- 또는 -Y-CO-(CH2)n또는 -Y-CO-(CH2)n인 화학식(Ⅰ)의 화합물을 제조하며(이 경우에, 한 반응물은 -YH그룹을 가지며 다른 반응물은 L그룹을 가지고, 하나의 반응물만이 -(CH2)n그룹을 가진다.; (d) 활성화된 형태의 화학식(Ⅱ)의 화합물을 -X-R5잔기를 제공하는 알데히드 또는 케톤과 반응시켜 X가 알칼인 화학식(Ⅰ)의 화합물을 제조하고; (e) R2가 수소인 화학식(Ⅰ)의 화합물을 화학식 R2-1의 요오드화 알킬과 반응시켜 R2가 C1-C3알킬인 화학식(Ⅰ)의 화합물을 제조하거나; 또는 (f) 생성물을 산화시켜 R 및 R1이 함께 단일결합을 형성하는 화학식(Ⅰ)의 화합물을 제조하거나; 또는 (g) X그룹을 산화 또는 환원시키거나; 또는 (h) 보호그룹을 제거하거나; 또는 (i) 염을 제조하거나; 또는 (j) 광학 이성질체를 단리하는 상기 화학식(Ⅰ)의 화합물의 제조방법 :※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/309,282 US5578724A (en) | 1994-09-20 | 1994-09-20 | Process for preparation of benzo[f]quinolinones |
US08/309,282 | 1994-09-20 | ||
PCT/US1995/011521 WO1996009046A1 (en) | 1994-09-20 | 1995-09-14 | 5α-REDUCTASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970705996A true KR970705996A (ko) | 1997-11-03 |
Family
ID=23197530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970701783A KR970705996A (ko) | 1994-09-20 | 1995-09-14 | 5알파-환원 효소 저해제(5alpha-reductase inhibitors) |
Country Status (17)
Country | Link |
---|---|
US (4) | US5578724A (ko) |
EP (1) | EP0703221B1 (ko) |
JP (1) | JPH08225533A (ko) |
KR (1) | KR970705996A (ko) |
AU (2) | AU3510295A (ko) |
BR (1) | BR9509015A (ko) |
CA (1) | CA2158609C (ko) |
CZ (1) | CZ82197A3 (ko) |
DE (1) | DE69526475T2 (ko) |
ES (1) | ES2173940T3 (ko) |
FI (1) | FI971156A (ko) |
HU (1) | HUT77947A (ko) |
MX (1) | MX9702035A (ko) |
NO (1) | NO307930B1 (ko) |
NZ (1) | NZ292819A (ko) |
PL (1) | PL319163A1 (ko) |
WO (1) | WO1996009046A1 (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635197A (en) * | 1995-03-21 | 1997-06-03 | Eli Lilly And Company | Treatment and prevention of prostatic cancer metastasis |
US5629007A (en) * | 1995-03-21 | 1997-05-13 | Eli Lilly And Company | Method of preventing prostatic cancer development |
US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
JP2001504816A (ja) * | 1996-10-30 | 2001-04-10 | イーライ・リリー・アンド・カンパニー | ベンゾ[f]キノリノンの合成 |
AU5594398A (en) * | 1996-12-09 | 1998-07-03 | Merck & Co., Inc. | Methods and compositions for preventing and treating bone loss |
US6037326A (en) * | 1996-12-31 | 2000-03-14 | Styczynski; Peter | Reduction of hair growth |
EP0926148A1 (en) * | 1997-12-23 | 1999-06-30 | Applied Research Systems Ars Holding N.V. | Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors |
US6632447B1 (en) | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6410043B1 (en) | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6048869A (en) * | 1998-07-29 | 2000-04-11 | Merck & Co., Inc. | Tricyclic compounds |
US6481721B1 (en) | 1999-07-15 | 2002-11-19 | Lucent Technologies Inc. | Method and apparatus for overcladding a glass rod |
US20020010528A1 (en) * | 2000-03-31 | 2002-01-24 | Imx Labs, Inc. | Nail Polish color selection system |
GB201102913D0 (en) | 2011-02-18 | 2011-04-06 | Univ Birmingham | Novel therapeutic |
US11370757B2 (en) * | 2017-10-18 | 2022-06-28 | Board Of Regents, The University Of Texas System | Photocleavable nitroindoline-based crosslinkers |
US11820439B2 (en) * | 2020-12-16 | 2023-11-21 | Steering Solutions Ip Holding Corporation | Power-assist assembly |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8302361D0 (sv) * | 1983-04-27 | 1983-04-27 | Astra Laekemedel Ab | New tricyclic amines |
US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
ZA883034B (en) * | 1987-04-29 | 1989-03-29 | Smithkline Beckman Corp | Steroid 5-alpha-reductase inhibitors |
US4923868A (en) * | 1989-02-21 | 1990-05-08 | American Cyanamid Company | 8-fluoro and 7,8,10-trifluoro-9-(substituted)-6-oxo-6H-benzo(C)quinolizine-5-carboxylic acids |
CA2011640A1 (en) * | 1989-03-20 | 1990-09-20 | Rene Imhof | Quinoline derivatives |
US5300294A (en) * | 1990-06-27 | 1994-04-05 | Smithkline Beecham Corporation | Method of treating prostatic adenocarcinoma |
IE76452B1 (en) * | 1990-10-29 | 1997-10-22 | Sankyo Co | Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use |
US5239075A (en) * | 1991-08-21 | 1993-08-24 | Eli Lilly And Company | Process for the preparation of benzo (f) quinolinones |
US5250539A (en) * | 1991-08-21 | 1993-10-05 | Eli Lilly And Company | Hexahydrobenzo[f]quinolinones |
ES2169026T3 (es) * | 1991-08-21 | 2002-07-01 | Lilly Co Eli | Benzo(f)quinolinonas como inhibidores de 5-alfa-reductasa. |
ES2125884T3 (es) * | 1991-08-21 | 1999-03-16 | Lilly Co Eli | Hexahidrobenzo(f)quinolinonas como inhibidores de la 5-alfa-reductasa. |
US5175155A (en) * | 1991-10-07 | 1992-12-29 | Sterling Winthrop Inc. | Win 49596-finasteride method of use and compositions |
TW224091B (ko) * | 1992-04-03 | 1994-05-21 | Lilly Co Eli | |
US5356935A (en) * | 1993-12-13 | 1994-10-18 | Eli Lilly And Company | Reduced phenanthrenes |
-
1994
- 1994-09-20 US US08/309,282 patent/US5578724A/en not_active Expired - Fee Related
-
1995
- 1995-05-11 US US08/439,396 patent/US5622961A/en not_active Expired - Fee Related
- 1995-05-11 US US08/439,405 patent/US5622962A/en not_active Expired - Lifetime
- 1995-09-14 WO PCT/US1995/011521 patent/WO1996009046A1/en not_active Application Discontinuation
- 1995-09-14 MX MX9702035A patent/MX9702035A/es unknown
- 1995-09-14 BR BR9509015A patent/BR9509015A/pt not_active Application Discontinuation
- 1995-09-14 PL PL95319163A patent/PL319163A1/xx unknown
- 1995-09-14 HU HU9801416A patent/HUT77947A/hu unknown
- 1995-09-14 CZ CZ97821A patent/CZ82197A3/cs unknown
- 1995-09-14 NZ NZ292819A patent/NZ292819A/xx unknown
- 1995-09-14 AU AU35102/95A patent/AU3510295A/en not_active Abandoned
- 1995-09-14 KR KR1019970701783A patent/KR970705996A/ko not_active Application Discontinuation
- 1995-09-18 ES ES95306551T patent/ES2173940T3/es not_active Expired - Lifetime
- 1995-09-18 DE DE69526475T patent/DE69526475T2/de not_active Expired - Lifetime
- 1995-09-18 EP EP95306551A patent/EP0703221B1/en not_active Expired - Lifetime
- 1995-09-19 CA CA002158609A patent/CA2158609C/en not_active Expired - Fee Related
- 1995-09-19 JP JP7240181A patent/JPH08225533A/ja not_active Ceased
-
1997
- 1997-03-18 NO NO971248A patent/NO307930B1/no not_active IP Right Cessation
- 1997-03-19 FI FI971156A patent/FI971156A/fi unknown
- 1997-04-18 AU AU18981/97A patent/AU692123B2/en not_active Ceased
-
1998
- 1998-12-11 US US09/210,106 patent/US6150375A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ292819A (en) | 1999-01-28 |
CA2158609C (en) | 2006-07-11 |
NO307930B1 (no) | 2000-06-19 |
AU692123B2 (en) | 1998-05-28 |
WO1996009046A1 (en) | 1996-03-28 |
DE69526475D1 (de) | 2002-05-29 |
US5622962A (en) | 1997-04-22 |
MX9702035A (es) | 1997-06-28 |
PL319163A1 (en) | 1997-07-21 |
AU1898197A (en) | 1997-06-26 |
EP0703221B1 (en) | 2002-03-27 |
BR9509015A (pt) | 1998-01-06 |
CA2158609A1 (en) | 1996-03-21 |
NO971248D0 (no) | 1997-03-18 |
FI971156A0 (fi) | 1997-03-19 |
JPH08225533A (ja) | 1996-09-03 |
DE69526475T2 (de) | 2002-09-26 |
EP0703221A1 (en) | 1996-03-27 |
FI971156A (fi) | 1997-03-19 |
US5578724A (en) | 1996-11-26 |
US5622961A (en) | 1997-04-22 |
AU3510295A (en) | 1996-04-09 |
US6150375A (en) | 2000-11-21 |
NO971248L (no) | 1997-03-18 |
ES2173940T3 (es) | 2002-11-01 |
HUT77947A (hu) | 1998-12-28 |
CZ82197A3 (cs) | 1998-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970705996A (ko) | 5알파-환원 효소 저해제(5alpha-reductase inhibitors) | |
EP1242404B1 (fr) | Phenoxypropanolamines, leur preparation et leur application en therapeutique | |
YU19002A (sh) | Derivati hinolil-propil-piperidina, njihovo dobivanje i smeše koje ih sadrže | |
BR0214164A (pt) | Ligantes do receptor canabinóide | |
RU98102128A (ru) | Производные бензо[g]хинолина | |
EP1354878A3 (en) | Tetrahydroquinoline derivatives having selective activity for retinoid x receptors | |
EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
RU93056600A (ru) | Фенокси- и феноксиалкилпиперидиновые соединения и антивирусная композиция | |
TR200301723T4 (tr) | 1,3 Dihidro-2H-indol-2 one türevleri ve bunların, arginin-vasopressin' in V1B veya V1B reseptörleri için bağ maddeleri olarak kullanımı | |
CA2011087A1 (en) | Use of trifluoromethylphenylazolylmethyloxiranes as crop protection agents | |
CO5251438A1 (es) | Derivados del acido hidroxamico sustituidos por arilsul- fonamido, compuestos y composiciones farmaceuticas que los contienen y procedimiento para su aplicacion y preparacion | |
DE69921151D1 (de) | Fluorszierende marker | |
RU2000102902A (ru) | Состав минеральной ваты и термо-звукоизоляционный продукт на его основе | |
KR900018048A (ko) | 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 | |
AR033300A1 (es) | Compuestos de cefem | |
EP1106167A3 (en) | Dye compositions for keratin fibers comprising a nonionic compound | |
DE50105454D1 (de) | Verfahren zur katalytischen Reduktion von Alkinverbindungen | |
BR9914438A (pt) | Processo aperfeiçoado para a preparação de novos agentes anti-diabéticos | |
KR840002363A (ko) | 살충제조성물 및 그 제조방법 | |
BR9812085A (pt) | "método para a sìntese de derivados de quinolina" | |
KR910011880A (ko) | 신규 화합물 | |
Conte et al. | Enantioselective oxidation of β-hydroxythioethers. Synthesis of optically active alcohols and epoxides | |
PE20030327A1 (es) | 3-5-dihidroxi-2,2-dimetil-valeronitrilos protegidos para la sintesis de epotilonas y sus derivados y metodo para su obtencion | |
ATE187160T1 (de) | Verfahren zur herstellung eines substituierten 2,5-diamino-3-hydroxy hexanes | |
WO2001051004A3 (en) | Anti-cancer agent containing naphthoquinone compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |